The bottleneck is organizational, not scientific
Across Finland's pharmaceutical companies, government agencies, and university research groups, a quiet negotiation is underway — one that will determine whether personalized medicine reaches patients or stalls in the space between competing visions. A University of Eastern Finland study, drawing on 23 stakeholder interviews, reveals that the field's greatest obstacle is not scientific uncertainty but the human difficulty of sustaining dialogue across fundamentally different institutional rhythms and interests. The research reminds us that even the most promising medical advances must pass through the crucible of collective sense-making before they can become collective benefit.
- Personalized medicine's promise is real, but it is being held hostage by a coordination problem: companies, public agencies, and academics each see the field through a different lens and move at a different pace.
- Companies routinely pull back from early-stage collaboration when the science is uncertain and the commercial return is invisible, creating a vacuum precisely where shared momentum is most needed.
- Three competing framings — clinical benefit, cost reduction, and market opportunity — coexist in the same rooms, sometimes enriching the conversation and sometimes quietly derailing it.
- Stakeholders are attempting to build shared direction not through formal mandates but through accumulated signals: a company's research commitment, a university's pivot, a government agency's funding shift.
- The study, published in Innovation: Organization & Management, lands a pointed conclusion — the bottleneck is organizational and social, not scientific, and no amount of laboratory progress will resolve it alone.
Personalized medicine is not a laboratory achievement waiting to happen in isolation — it is a negotiation, playing out in conference rooms and email chains between people who see the same field through fundamentally different lenses. A new University of Eastern Finland study offers a window into how this negotiation actually works, and why it so often stumbles.
Researchers conducted 23 interviews with the key players shaping personalized medicine in Finland: pharmaceutical and biotech companies, government health agencies, and university research groups. What emerged was a portrait of an ecosystem trying to build a shared future while operating from separate playbooks. The actors involved are not enemies, but they are not naturally aligned either — some emphasize clinical promise, others the economic case for targeted interventions, and still others the technological and business opportunities the field might unlock.
What holds these different visions together is dialogue. Shared understanding does not arrive through formal agreements or top-down mandates; it accumulates through ongoing conversation, where signals from one party gradually reshape the behavior of others. But the process is fragile. Companies hesitate to engage when science is uncertain and commercial payoff is unclear. Academic timelines, corporate market pressures, and government budget cycles rarely synchronize, and when they fall out of step, momentum stalls and misunderstanding can harden into suspicion.
Postdoctoral researcher Ida Parkkinen framed the core tension plainly: continuous dialogue is essential, but difficult to sustain when underlying interests diverge. The findings carry weight beyond Finland — healthcare systems worldwide are encountering the same friction. The study's quiet conclusion is that the bottleneck is not scientific but organizational and social, and that accelerating personalized medicine will require investing not just in the research itself, but in the structures that allow different institutions to build and maintain shared understanding over time.
Personalized medicine is not a laboratory achievement waiting to happen in isolation. It is a negotiation—one that plays out in conference rooms and email chains between people who see the same field through fundamentally different lenses. A new study from the University of Eastern Finland offers a window into how this negotiation actually works, and why it so often stumbles.
Researchers conducted 23 interviews with the key players shaping personalized medicine in Finland: pharmaceutical and biotech companies, government health agencies, and university research groups. What emerged was a portrait of an ecosystem trying to build a shared future while operating from separate playbooks. The stakeholders involved—companies seeking profit, public institutions focused on health outcomes, academics pursuing knowledge—are not enemies. But they are not naturally aligned either.
The study identified three distinct ways these actors frame what personalized medicine could become. Some emphasize the clinical promise: better health outcomes, more precise treatments, fewer side effects. Others focus on the economic argument: the potential to reduce healthcare costs by targeting interventions to those most likely to benefit. Still others are primarily interested in the technological and business opportunities the field might unlock—new markets, new capabilities, new ways of organizing healthcare delivery. All three framings are present in the same conversations, sometimes in tension.
What holds these different visions together is dialogue. Stakeholders do not arrive at shared understanding through formal agreements or top-down mandates. Instead, they build it through ongoing conversation where each party interprets what is happening in the field and makes bets about what comes next. A company might signal its commitment to a particular research direction; a university team might respond by reorienting its work; a government agency might adjust its funding priorities. Over time, these signals accumulate into something resembling a collective sense of direction.
But the process is fragile. The study found that companies often hesitate to participate in early-stage innovation work, particularly when the science is still uncertain and the commercial payoff is unclear. Different stakeholders move at different speeds. Academic researchers operate on grant cycles and publication timelines; companies need to see a path to market; government agencies balance competing priorities and budget constraints. When these rhythms do not align, momentum stalls. Misunderstandings about what each party is trying to accomplish can harden into mutual suspicion.
Ida Parkkinen, a postdoctoral researcher involved in the study, framed the core challenge plainly: aligning different goals and perspectives requires continuous dialogue, but that dialogue is difficult to sustain when the underlying interests diverge. A company betting on a particular genetic marker as a diagnostic tool may not share the public health agency's concern about equitable access. An academic team pursuing a fundamental discovery may not prioritize the practical applications a company needs to justify its investment.
The findings matter beyond Finland. Healthcare systems worldwide are trying to integrate personalized medicine into practice, and they are discovering the same friction points. The study, published in Innovation: Organization & Management, suggests that the bottleneck is not primarily scientific or technical. It is organizational and social. The question is not whether personalized medicine works—in many cases, it does. The question is whether the institutions that need to collaborate to bring it to patients can actually do so at the pace and scale the field requires.
That remains an open question. The study does not offer a solution, only a clearer map of the terrain. For policymakers and research leaders trying to accelerate personalized medicine, the implication is clear: invest not just in the science, but in the structures and processes that allow different stakeholders to build and maintain shared understanding over time.
Notable Quotes
The key challenge is aligning different goals and perspectives through continuous dialogue between stakeholders— Ida Parkkinen, Postdoctoral Researcher, University of Eastern Finland
The Hearth Conversation Another angle on the story
Why does personalized medicine need all these different groups talking to each other? Can't companies just develop it on their own?
Because personalized medicine is not just a product—it is a system. You need the science from universities, the regulatory pathway from government, the manufacturing and distribution from industry, and ultimately the clinical integration from hospitals and health systems. No single actor has all the pieces.
So what goes wrong when they try to work together?
They are operating on different timelines and with different measures of success. A company needs to see a return on investment within a few years. A university researcher might be working on a five-year grant. A government agency is thinking about population health over a decade. When those rhythms do not sync, people stop showing up to the meetings.
The study mentions "differing interests." What does that actually mean in practice?
It means a company might want to focus on a diagnostic test for a wealthy market, while a public health agency wants to ensure the same test is available and affordable to everyone. Both goals are reasonable. They are just not the same goal, and reconciling them takes work that nobody is formally paid to do.
Is there a way to make that reconciliation happen more reliably?
The study suggests the answer is continuous dialogue—but not the kind that happens once a year at a conference. It means building relationships and communication structures that allow people to adjust course as new information emerges. That requires trust, and trust takes time to build.